JRT (drug)

EN Texto en inglés Aún no hay artículo en tu idioma: extracto en inglés.

JRT, also known as isotryptamine-LSD, is a serotonin receptor modulator, psychoplastogen, and serotonergic psychedelic related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the embedded tryptamine structure within the ergoline ring system of LSD has been replaced with an isotryptamine structure. The drug acts as a non-selective serotonin receptor modulator, including as a partial agonist of the serotonin 5-HT2A receptor and as an agonist or antagonist of various other serotonin receptors. The drug has psychedelic-like, psychoplastogenic, antipsychotic-like, antidepressant-like, and pro-cognitive effects in animals and preclinical studies, whilst lacking apparent pro-psychotic-like effects. It has significant but reduced psychedelic-like effects compared to LSD in animals. The drug is a racemic mixture of (+)- and (–)- enantiomers, with (+)-JRT being the active and employed form. JRT was first described in the scientific literature by 2022 and was described in greater detail in 2025. It was developed by David E. Olson and colleagues in association with Delix Therapeutics. The drug is being investigated as a possible treatment for schizophrenia. The properties and effects of JRT in humans do not yet appear to be known.